Cellmid Launches Évolis (TM) Hair Products
|| Print ||
|Thursday, 29 March 2012 09:30 (UTC + 2)|
The first clinically validated hair growth product to be released in over two decades
Sydney, Australia, Thursday, 29 March 2012 / B3C newswire / - Cellmid Limited (ASX: CDY) advises that it has commenced the commercial launch of its Évolis™ hair growth products with an event in Sydney for representatives of the national printed and electronic media yesterday. The products have received celebrity endorsement from Paula Duncan, AM. The press release for the event can be accessed here.
In February 2012 Cellmid advised that it had received TGA approval and expected completion of the GMP manufacture and commercial launch of the Évolis™ products in May 2012. These events have now been brought forward and commercial sale of the products through pharmacies is likely to commence in the middle of the calendar year, three months earlier than previously planned.
The Évolis™ for Men and Évolis™ for Women products have important TGA approved claims of “promotes hair growth”, “helps prevent hair loss and thinning” and “restores the natural hair growth cycle”.
The Évolis™ products will not require a prescription and will be sold as over the counter medicines in individual pharmacies as well as pharmacy chains at the recommended retail price of $89 for each 50 ml bottle. The Company is targeting a minimum of 400 pharmacies nationally within the first twelve months.
It is estimated that 40% of women and 50% of men in western countries are affected by hair loss at some stage in their life. Current hair growth products either have serious side effects or lack evidence of efficacy. The key competitive advantage for the Évolis™ range is safety combined with efficacy and as such the products represent a significant market opportunity.
Cellmid, via its wholly owned subsidiary Advangen International Pty Ltd, holds exclusive manufacturing and distribution rights for the products in Australia, USA, Europe, India and South America with significant combined sales potential. Commercial launch outside Australia is expected to commence in late 2012.
The website for the Évolis™ products will be re-launched on 15th April 2012 with a commercial interface to facilitate internet sales and a promotional video which will also be released on site in participating pharmacies.
About Advangen International Pty Ltd
About Advangen’s Products